Work

Radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin) does not preclude subsequent radiotherapy or other antilymphoma therapies: Updated safety and efficacy data

Year: 2004

Type: article

Source: International Journal of Radiation Oncology*Biology*Physics

DOI: 10.1016/j.ijrobp.2004.07.513

Authors: R.J. Schilder, A. Molina, L.I. Gordon, C. Emmanouilides, M.S. Czuczman, H. Wang, T.E. Witzig, S.M. Ansell, C.A. White

Institutions: Fox Chase Cancer Center, Biogen (United States), Northwestern University, University of California, Los Angeles, Roswell Park Comprehensive Cancer Center, Mayo Clinic

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2139355428

FWCI: 0.267

Cites:

Cited by: 1

Related to: 10